Latest Breaking News On - Tissue specific therapeutics - Page 11 : comparemela.com

U S Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children

U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children - read this article along with other careers information, tips and advice on BioSpace

United statesIlya rachmanGabriel morrisImmix biopharma incDrug administrationGovernment accountability officeRare pediatric disease designationImmix biopharmaGovernment accountabilityTissue specific therapeuticsRare pediatric diseaseNew drug applicationPriority review voucherChief executive officer ilya rachmanImmix biopharma corporate presentationSystem multi action regulators

ImmixBio Announces FDA Orphan Drug Designation for IMX-110 for the Treatment of Soft Tissue Sarcoma

ImmixBio Announces FDA Orphan Drug Designation for IMX-110 for the Treatment of Soft Tissue Sarcoma
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesGabriel morrisImmix biopharma incNormalization technologyPrnewswire immix biopharma incDrug administrationHtm technologyOffice of orphan products developmentTissue specific therapeuticsOrphan products developmentDrug designationIlya rachmanImmixbio founderImmixbio chief financial officerSystem multi action regulatorsImmix biopharma

ImmixBio Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid Tumors

ImmixBio Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid Tumors
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesIlya rachmanGabriel morrisPrnewswire immix biopharma incBeigene ltdImmix biopharma incExchange commissionChina national medical products administrationNormalization technologyTissue specificTissue specific therapeuticsNorth americaSystem multi action regulatorsSecurities litigation reform act

ImmixBio Announces Dr George W Sledge of Stanford University Medical Center Joins Scientific Advisory Board

ImmixBio Announces Dr George W Sledge of Stanford University Medical Center Joins Scientific Advisory Board
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesIlya rachmanGabriel morrisIndiana university simon cancer centerOncology drug advisory committeeIndiana university cancer centerAmerican society of clinical oncologyOncology at stanford university medical centerPrnewswire immix biopharma incTulane universityAdvisory committeeHope funds for cancer researchUniversity of wisconsinImmix biopharma incPathology of indiana university school medicineTissue specific therapeutics

ImmixBio Announces Dr Jane Buchan Joins Board of Directors

ImmixBio Announces Dr Jane Buchan Joins Board of Directors
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesReed collegeIlya rachmanJane buchanGabriel morrisUniversity of california irvine foundationYale universityCompany board of directorsManagement ltdPrisma holdingsImmix biopharma incTrustee of reed collegeCapital markets groupHarvard universityGlobe life incAmos tuck school of business at dartmouth